期刊文献+

原发性胆汁性肝硬化临床分期的意义 被引量:3

Application of clinical staging for primary biliary cirrhosis
原文传递
导出
摘要 目的探讨原发性胆汁性肝硬化(PBC)临床分期的意义。方法观察不同时段(1995—1998年13例、1999-2002年11例、2003--2007年66例)确诊的90例PBC患者的临床表现,检测其生化指标,并行肝穿刺活组织检查,对比治疗效果。结果近年来PBC的早期诊断率明显提高,2003年以后共发现症状发生前期患者2例和无症状期患者19例。无症状期患者中4例有门静脉高压、7例有肝脾肿大的辅助检查证据。临床期和失代偿期患者瘙痒、黄瘤、骨病和夜盲症发生率差异无统计学意义(P值均〉0.05),但乏力、黄疸、门静脉高压、腹水和并发其他免疫性疾病的发生率差异有统计学意义(P值均〈0.05)。各时段患者的碱性磷酸酶和IgM水平差异有统计学意义(P〈0.05)。γ-谷氨酰转肽酶水平在症状发生前期[(36.75±1.77)μmol/L]、无症状期[(303.71±82.15)μmol/L]和症状期[(513.68±289.85)μmol/L]间差异有统计学意义(P〈0.01)。无症状期和症状期的组织学改变可表现为病理学分期中的任何一期。熊去氧胆酸无症状期治疗可使生化指标获明显改善,症状期治疗所获生化指标和症状改善程度优于失代偿期。结论强调PBC临床分期可促进临床PBC的早期诊断,随之的早期治疗可获较好疗效和预后。 Objective To investigate the clinical staging for primary biliary cirrhosis(PBC). Methods Ninety six patients diagnosed of PBC in three periods(1995 1998, 13 cases; 1999--2002, 11 cases; 2003--2007, 66 cases)were enrolled and their clinical manifestation and biochemical indictors were observed. The liver biopsy and therapeutic effects were evaluated. Results The early diagnostic rate had increased in recent years. Since 2003, 19 asymptomatic(4 with portal hypertention and 7 with splenohepatomegalia) and 2 early presymptomatic cases were diagnosed. There was no statistical difference in pruritus, lipoid granuloma, osteopathis, and night-blindness between symptomatic and decompensated patients (P 〉 0.05), while there was significant difference in lethargy, jaundice, portal hypertension, ascites, splenohepatomegalia and the incidence of other immune diseases between two groups (P〈0.05). There was significant difference in levels of alkaline phosphatase and IgM among patients in three periods. The levels of GGT were 36.75±1.77, 303. 71±82.15, 513. 68± 289.85 of μmol/L in presymptomatic, asymptomatic and symptomatic stage, respectively (P 〈 0.01). The patients in asymptomatic and symptomatic stage had histological changes of any pathologic stage. Ursodeoxycholic acid treatment could improve biochemical indicator of asymptomatic patients. The outcome of patients received treatment in asymptomatic stage was better than those in symptomatic stage. Conclusions The clinical staging may result of early diagnosis of PBC and the early treatment will be more effective.
出处 《中华消化杂志》 CAS CSCD 北大核心 2008年第1期7-10,共4页 Chinese Journal of Digestion
关键词 肝硬化 胆汁性 肝脏/病理学 熊去氧胆酸 Liver cirrhosis, biliary Liver/Pathology Ursodeoxycholic acid
  • 相关文献

参考文献9

  • 1Harada K, Hakanuma Y. Molecular mechanisms of cholangiopathy in primary biliary cirrhosis. Med Mol Morphol, 2006, 39:55-61.
  • 2姚光弼.中国人原发性胆汁性肝硬化的前瞻性研究[J].肝脏,2002,7(3):146-149. 被引量:63
  • 3Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology, 2000, 31:1005-1013.
  • 4沈麦琪 沈晓黎 等.复合组织切片技术在测定自身抗体中的应用[J].上海免疫学杂志,1984,4:167-167.
  • 5Bassendine MF, Yeaman SJ. Serological markers of primary biliary cirrhosis: diagnosis, prognosis and subsets. Hepatology, 1992, 15:545-548.
  • 6Mitchison HC, Bassendine MF, Hendrick A, et al. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology, 1986, 6 : 1279-1284.
  • 7Metcalf JV, Mitchison HC, Palmer JM, et al. Natural history of early primary biliary cirrhosis. Lancet, 1996, 348 : 1399-1402.
  • 8Poupon RE, Lindor KD, Pares A, et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol, 2003, 39: 12-16.
  • 9Nakano T, Inoue K, Hirohara J, et al. Long-term prognosis of primary biliary cirrhosis(PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC(a-PBC). Hepatol Res, 2002, 22:250-260.

二级参考文献5

共引文献63

同被引文献24

  • 1陈燕,龙波,姚定康,周晔,蒋天舒,谷明莉,陈波,仲人前,邓安梅.原发性胆汁性肝硬化患者外周血T淋巴细胞亚群检测的意义[J].临床检验杂志,2007,25(1):34-35. 被引量:8
  • 2Selmi C, Bowlus CL, Gershwin ME, et al. Primary biliary cirrhosis [J]. Lancet, 2011, 377(9777) : 1600-1609.
  • 3Dai R, Ahmed SA. MieroRNA, a new paradigm for understanding immunoregulatian, inflammation, and autoimmune diseases [ J ]. Transl Res, 2011, 157(4) : 163-179.
  • 4Murata K, Yoshitomi H, Tanida S, et al. Research article plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis[J]. Arthristis Res Ther, 2010,12(3) : 86-88.
  • 5Wei X, Tan C, Tang C, et al. Epigenetic repression of miR-132 ex- pression by the hepatitis B virus X protein in hepatitis B virus-related hepatocellular carcinoma [ J]. Cell Signal, 2013, 25 (5) : 1037- 1043.
  • 6Heathcote EJ. Management of primary biliary cirrhosis. The American association for the study of liver diseases practice guidelines [ J ]. Hep- atology,2000,31 (4) :1005-1013.
  • 7Padgett KA, Lan RY, Leung PC, et al. Primary biliary cirrhosis is associated with altered hepatic microRNA expression [ J ]. J Autoim- mu, 2009, 32(3): 246-253.
  • 8Huang Y, Lei YF, Zhang H, et al. MicmRNA regulation of STAT4 protein expression: rapid and sensitive modulation of IL-12 signaling in human natural killer cells [ J ]. Blood, 2011, 118 (26) : 6793- 6802.
  • 9Pak TR, Rao YS, Prins SA, et al. An emerging role for microRNAs in sexually dimorphic neurohiological systems [ J ]. Pflugers Arch, 2013,465(5) :655-667.
  • 10Park JK, Henry JC, Jiang J, et al. miR-132 and miR-212 are in-creased in pancreatic cancer and target the retinoblastoma tumor suppressor[J].Biochem Biophys Res Commun, 2011, 406 (4) : 518-523.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部